日本TaKaRa  www.takara.com.cn  www.takara-bio.com  www.takara.co.jp
TaKaRa Bio Group是世界三大生物工程公司之一，其相關(guān)產(chǎn)品在日本市場(chǎng)上的占有率達(dá)60%以上，并暢銷國(guó)際市場(chǎng)。大連TaKaRa公司成立于1993年8月，公司生產(chǎn)和開(kāi)發(fā)生物工程研究用試劑，有DNA限制酶、修飾酶、各種基因操作試劑盒、PCR相關(guān)產(chǎn)品等，還開(kāi)展DNA合成、DNA測(cè)序、DNA芯片制作以及其他各種基因工程操作等的全方位服務(wù)。此外，TaKaRa還擁有實(shí)驗(yàn)條件一流的開(kāi)放實(shí)驗(yàn)室，可以為科研人員的實(shí)驗(yàn)順利進(jìn)行提供良好條件。現(xiàn)在公司生產(chǎn)的產(chǎn)品除在中國(guó)國(guó)內(nèi)進(jìn)行銷售外，有70%出口海外。
寶生物工程(大連)有限公司是由日本TaKaRa Bio株式會(huì)社在中國(guó)大連經(jīng)濟(jì)技術(shù)開(kāi)發(fā)區(qū)投資興建的日本獨(dú)資企業(yè)。

技術(shù)咨詢熱線： 0411-87641685，87641686 
800免費(fèi)咨詢熱線： 8008909508
400咨詢熱線： 4006518769
傳 真： 0411-87619946，87621675
E-mail： service@takara.com.cn

訂貨方法 

我們的聯(lián)絡(luò)信息如下: 
地 址：遼寧省大連市經(jīng)濟(jì)技術(shù)開(kāi)發(fā)區(qū)東北二街19號(hào) (116600)
公司名稱：寶生物工程(大連)有限公司 
電 話：0411-87641681, 87641683 
傳 真：0411-87621675, 87619946 
E-mail：
reagent@takara.com.cn (試劑訂貨) 
order@takara.com.cn (試劑訂貨－大連地區(qū)) 
oligo@takara.com.cn (合成DNA) 
gact1@takara.com.cn (DNA測(cè)序)

Since its beginnings as the biomedical business of Takara Shuzo Co., Ltd. (now Takara HoldingssInc.), Takara Bio has continuously expanded its gene and DNA-related businesses, which havesnow developed into three business segments. In 1979, the Genetic engineering research businessswas launched with the sale of the first domestically produced restriction enzymes. This businessshas now expanded to include a portfolio of genetic engineering research reagents, scientificsinstruments and contract research services that are essential to biotechnology researcherssworldwide. In the AgriBio segment, which was the first to succeed in the large-scale cultivationsof Bunashimeji mushrooms in 1970, we promote a mushroom business that is centered onstechnologies for the large-scale cultivation of mushrooms. We also offer customers such foodsmaterials as kombu (kelp) "fucoidan," agar (vegetable gelatin) "agaoligo," Ashitaba (angelicasherb) "chalcone" and mushroom "terpene," whose functionality has been proven through thesuse of biotechnology. In the Gene medicine segment, we are striving to develop andscommercialize cutting-edge medical technologies, such as gene and cell therapies for cancer andsAIDS, based on technologies developed and accumulated through the activities of our Geneticsengineering research segment.
Our business strategyis to invest the stable income generated by the Genetic engineering research and AgriBio segments into the Gene medicine segment in order to develop gene medicine technologies, thereby expanding our future earnings.
Takara Bio Inc. contributes to the health of mankind by making revolutionary biomedical technology, such as gene therapy, a reality.